NASDAQ : GENB
Generate Biomedicines, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 14.46 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.86B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Generate Biomedicines, Inc. (GENB) reported revenue of 26.48M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 26.48M | 31.89M | 20.46M |
| Cost of Revenue | 240.28M | 224.70M | 175.31M |
| Gross Profit | -213.80M | -192.81M | -154.85M |
| Selling, General & Admin | 48.69M | 42.26M | 42.09M |
| Operating Expenses | 48.69M | 42.26M | 42.09M |
| Operating Income | -262.49M | -235.06M | -196.94M |
| Interest Expense | -798.00K | -1.14M | -2.12M |
| Interest & Investment Income | 13.13M | 13.66M | 18.12M |
| Currency Exchange Gain (Loss) | -106.00K | -149.00K | -79.00K |
| Other Non Operating Income (Expenses) | -476.00K | -113.00K | -154.00K |
| Pretax Income | -250.73M | -222.80M | -181.17M |
| Income Tax Expense | 144.00K | 163.00K | 212.00K |
| Earnings From Continuing Operations | -250.88M | -222.97M | -181.38M |
| Minority Interest in Earnings | 13.14M | 19.81M | 7.61M |
| Net Income | -237.74M | -203.15M | -173.77M |
| Preferred Dividends & Other Adjustments | 30.93M | 46.37M | 40.01M |
| Net Income to Common | -268.67M | -249.52M | -213.78M |
| Shares Outstanding (Basic) | 82.01M | 50.09M | 48.74M |
| Shares Outstanding (Diluted) | 82.01M | 50.09M | 48.74M |
| EPS (Basic) | -3.28 | -4.98 | -4.39 |
| EPS (Diluted) | -3.28 | -4.98 | -4.39 |
| Free Cash Flow | -244.34M | -204.13M | -121.20M |
| Free Cash Flow Per Share | -2.98 | -4.08 | -2.49 |
| Operating Margin | -991.15% | -737.04% | -962.60% |
| Profit Margin | -1,014.51% | -782.38% | -1,044.90% |
| Free Cash Flow Margin | -922.65% | -640.06% | -592.39% |
| EBITDA | -249.55M | -221.89M | -181.59M |
| D&A For EBITDA | 12.94M | 13.18M | 15.35M |
| EBIT | -262.49M | -235.06M | -196.94M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 135.36M | 121.65M | 176.27M |
| Short-Term Investments | 322.06M | 99.85M | 217.36M |
| Cash & Short-Term Investments | 457.42M | 221.50M | 393.63M |
| Receivables | 308.00K | ||
| Prepaid Expenses | 12.84M | 12.53M | 12.13M |
| Restricted Cash | 339.00K | 1.43M | |
| Total Current Assets | 470.25M | 234.37M | 407.49M |
| Property, Plant & Equipment | 82.38M | 89.01M | 101.07M |
| Other Long-Term Assets | 9.06M | 6.81M | 9.70M |
| Total Assets | 561.69M | 330.18M | 518.26M |
| Accounts Payable | 5.55M | 3.84M | 5.67M |
| Accrued Expenses | 22.78M | 39.54M | 19.34M |
| Current Portion of Leases | 13.62M | 15.01M | 16.72M |
| Current Unearned Revenue | 12.17M | 21.19M | 42.42M |
| Other Current Liabilities | 2.52M | 2.63M | 2.48M |
| Total Current Liabilities | 56.64M | 82.20M | 86.63M |
| Long-Term Leases | 49.01M | 53.52M | 60.26M |
| Long-Term Unearned Revenue | 4.51M | 15.17M | |
| Other Long-Term Liabilities | 116.00K | 349.00K | |
| Total Liabilities | 105.64M | 140.35M | 162.40M |
| Common Stock | 128.00K | 50.00K | 50.00K |
| Additional Paid-In Capital | 1.26B | 60.17M | 38.45M |
| Retained Earnings | -804.99M | -676.29M | -473.14M |
| Comprehensive Income & Other | -129.00K | 106.00K | 118.00K |
| Total Common Equity | 456.05M | -615.97M | -434.52M |
| Minority Interest | -7.23M | -571.00K | |
| Shareholders' Equity | 456.05M | 189.83M | 355.86M |
| Total Liabilities & Equity | 561.69M | 330.18M | 518.26M |
| Total Debt | 62.63M | 68.53M | 76.97M |
| Net Cash (Debt) | 394.79M | 152.97M | 316.65M |
| Net Cash Per Share | 4.81 | 3.05 | 6.50 |
| Filing Date Shares Outstanding | 128.35M | 50.30M | 49.66M |
| Total Common Shares Outstanding | 128.27M | 50.30M | 49.66M |
| Working Capital | 413.62M | 152.16M | 320.87M |
| Book Value Per Share | 3.56 | -12.24 | -8.75 |
| Tangible Book Value | 456.05M | -615.97M | -434.52M |
| Tangible Book Value Per Share | 3.56 | -12.24 | -8.75 |
| Machinery | 48.00M | 42.92M | 19.61M |
| Construction In Progress | 1.47M | 4.11M | 886.00K |
| Leasehold Improvements | 11.26M | 9.66M | 9.63M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -237.74M | -203.15M | -173.77M |
| Depreciation & Amortization | 12.94M | 13.18M | 15.35M |
| Loss (Gain) From Sale of Assets | -64.00K | -64.00K | -10.00K |
| Loss (Gain) From Sale of Investments | -1.60M | -2.78M | -5.45M |
| Stock-Based Compensation | 24.98M | 20.58M | 19.46M |
| Other Operating Activities | -4.61M | -13.76M | -1.45M |
| Change in Accounts Receivable | 340.00K | 308.00K | -213.00K |
| Change in Accounts Payable | -179.00K | -2.13M | 3.50M |
| Change in Unearned Revenue | -26.48M | -31.89M | 34.54M |
| Change in Other Net Operating Assets | -4.60M | 19.10M | -9.71M |
| Operating Cash Flow | -237.02M | -200.62M | -117.75M |
| Capital Expenditures | -7.32M | -3.51M | -3.45M |
| Sale of Property, Plant & Equipment | 10.00K | ||
| Investment in Securities | -161.00M | 120.28M | -54.29M |
| Investing Cash Flow | -168.32M | 116.77M | -57.73M |
| Long-Term Debt Repaid | -8.16M | -11.12M | |
| Net Debt Issued (Repaid) | -5.21M | -8.16M | -11.12M |
| Issuance of Common Stock | 373.38M | 1.10M | 1.13M |
| Other Financing Activities | 17.87M | 13.12M | 5.00M |
| Financing Cash Flow | 386.07M | 28.06M | 91.33M |
| Net Cash Flow | -19.27M | -55.79M | -84.15M |
| Free Cash Flow | -244.34M | -204.13M | -121.20M |
| Free Cash Flow Margin | -922.65% | -640.06% | -592.39% |
| Free Cash Flow Per Share | -2.98 | -4.08 | -2.49 |
| Levered Free Cash Flow | -119.10M | ||
| Unlevered Free Cash Flow | -118.39M | ||
| Cash Income Tax Paid | 163.00K | 163.00K | 212.00K |
| Change in Working Capital | -30.92M | -14.62M | 28.12M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.86B | ||
| Enterprise Value | 1.46B | ||
| Debt / Equity Ratio | 0.14 | 0.36 | 0.22 |
| Net Debt / Equity Ratio | -0.87 | -0.81 | -0.89 |
| Net Debt / EBITDA Ratio | 1.58 | 0.69 | 1.74 |
| Net Debt / FCF Ratio | 1.62 | 0.75 | 2.61 |
| Asset Turnover | 0.07 | ||
| Quick Ratio | 8.08 | 2.69 | 4.55 |
| Current Ratio | 8.30 | 2.85 | 4.70 |
| Return on Equity (ROE) | -81.72% | ||
| Return on Assets (ROA) | -34.63% | ||
| Return on Capital Employed (ROCE) | -52.00% | -94.80% | -45.60% |
| Buyback Yield / Dilution | -2.77% |